This webinar presents the history, introduction, applications, and regulatory considerations for liposomal drugs and also discusses the development and validation of LC-MS/MS methods for the quantitation of total (encapsulated plus free), encapsulated, and free drug concentrations for liposome drug products.
Register to gain access to gated resources.
Thank you for registering!
You may now view the resource below.
In this podcast, we discuss delivery modalities for sterile product development of poorly water-soluble drugs, with our special guest: Dr. Manish Mujal, Director of Product Development and CTM Manufacturing at Frontage Laboratories, Inc.
In this eBook, we explore the various ways LC-MS is utilized for the bioanalysis of ADCs and the strategies used for ADCs in biotherapeutics and clinical development.
Oligonucleotide (OGN) therapy is increasingly recognized as an important therapeutic modality with the promise of curing diseases. However, unlike most biotherapeutics, the development of OGN drugs often requires their determination with high sensitivity and specificity in multiple, complex biologic matrices such as blood and tissues in order to measure their exposure and distribution for understating PK, PD, and safety.
At Frontage Laboratories (PA, USA), we have developed highly sensitive and specific quantitative methods for the determination of OGN in plasma and tissues using hybridization immunoassay and LC–MS techniques. In this webinar, we will present the method development, validation, and comparison of these techniques for the quantification of OGN as well as a case study with antisense OGN.